BTIG Research Reiterates “Buy” Rating for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a note issued to investors on Thursday,Benzinga reports. They presently have a $112.00 price target on the medical equipment provider’s stock. BTIG Research’s price objective suggests a potential upside of 20.67% from the company’s previous close.

Several other equities analysts have also commented on the company. Royal Bank Of Canada dropped their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Barclays decreased their price target on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a report on Wednesday, November 5th. UBS Group dropped their price objective on Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating for the company in a report on Thursday, November 6th. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $94.00 to $120.00 in a report on Monday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $108.30.

Zimmer Biomet Trading Down 2.0%

Shares of ZBH stock opened at $92.82 on Thursday. The company has a market capitalization of $18.39 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.42 and a beta of 0.62. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $92.31 and a 200 day moving average price of $96.57. Zimmer Biomet has a twelve month low of $85.33 and a twelve month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Key Financial Inc boosted its stake in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. boosted its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares in the last quarter. Root Financial Partners LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter worth about $31,000. Finally, Mather Group LLC. acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.